Want to see SE:BIOVIC.B full AI Analyst Report?
Top Page
Biovica International AB Class B
(BIOVIC.B)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.36
▲(3.43% Upside)
Action:Reiterated
Date:10/03/26
The score is held down primarily by weak financial quality—negative gross profit, very large losses, and heavy free-cash-flow burn—despite improving revenue and a reduction in losses versus earlier years. Technicals add pressure as the stock trades below key moving averages with negative MACD, even though RSI suggests oversold conditions. Valuation contributes only modestly because the negative P/E reflects ongoing losses and there is no dividend yield provided.
Positive Factors
Revenue Growth
Rising TTM revenue indicates improving commercial traction for the DiviTum-focused business. If growth persists, greater scale could help absorb the current cost base, expand clinical adoption, and support a path toward stronger operating leverage over the next several quarters.
Negative Factors
Severe Unprofitability
Negative gross profit and deeply negative operating and net margins show that current revenue does not cover the direct and broader cost base. This weak economics limits self-funded growth, delays potential break-even, and leaves the business exposed to continued financing needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rising TTM revenue indicates improving commercial traction for the DiviTum-focused business. If growth persists, greater scale could help absorb the current cost base, expand clinical adoption, and support a path toward stronger operating leverage over the next several quarters.
Read all positive factors
Biovica International AB Class B (BIOVIC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr107.14M
Dividend YieldN/A
Average Volume (3M)406.08K
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue Growth56.06%
EPS Growth63.95%
CountrySE
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.25
Shares Outstanding277,487,200
10 Day Avg. Volume223,641
30 Day Avg. Volume406,080
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.95
Price to Sales (P/S)6.14
P/FCF Ratio-1.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr25.70M
Biovica International AB Class B Business Overview & Revenue Model
Company Description
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of...
Biovica International AB Class B Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.83M | 13.38M | 8.62M | 7.29M | 3.38M | 2.04M |
| Gross Profit | -47.52M | -70.05M | 8.08M | 6.88M | 4.62M | 4.67M |
| EBITDA | -63.18M | -61.75M | -76.22M | -114.42M | -102.19M | -53.47M |
| Net Income | -72.23M | -69.86M | -87.62M | -124.82M | -110.49M | -60.00M |
Balance Sheet | ||||||
| Total Assets | 90.07M | 107.75M | 64.95M | 131.41M | 172.29M | 151.63M |
| Cash, Cash Equivalents and Short-Term Investments | 51.59M | 70.41M | 24.41M | 79.41M | 114.33M | 89.79M |
| Total Debt | 6.02M | 4.30M | 4.65M | 7.83M | 10.45M | 13.25M |
| Total Liabilities | 23.50M | 21.42M | 21.74M | 34.77M | 33.65M | 27.54M |
| Stockholders Equity | 66.57M | 86.33M | 43.21M | 96.64M | 138.63M | 124.09M |
Cash Flow | ||||||
| Free Cash Flow | -64.04M | -63.28M | -85.65M | -114.72M | -97.42M | -55.52M |
| Operating Cash Flow | -61.71M | -62.81M | -85.37M | -114.58M | -94.64M | -52.13M |
| Investing Cash Flow | -2.33M | -474.00K | -287.00K | -585.00K | -2.78M | -3.40M |
| Financing Cash Flow | 99.41M | 109.36M | 30.93M | 79.50M | 122.01M | -136.00K |
Biovica International AB Class B Technical Analysis
Positive
0.35
Price Trends
0.34
Positive
0.39
Negative
0.38
Negative
Market Momentum
>-0.01
Negative
68.11
Neutral
77.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Positive. The current price of 0.35 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.34, and below the 200-day MA of 0.38, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 68.11 is Neutral, neither overbought nor oversold. The STOCH value of 77.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOVIC.B.
Biovica International AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr369.30M | 4.86 | 94.09% | ― | 135.48% | ― | |
74 Outperform | kr471.41M | 2.46 | 63.09% | ― | ― | ― | |
56 Neutral | kr38.05M | 13.56 | 21.37% | ― | 837.37% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr182.86M | -7.75 | -56.09% | ― | ― | 14.10% | |
45 Neutral | kr107.14M | -1.49 | -75.51% | ― | 56.06% | 63.95% | |
43 Neutral | kr31.94M | -0.85 | -106.23% | ― | -97.37% | 25.28% |
* Healthcare Sector Average
SE:BIOVIC.B
Biovica International AB Class B
0.36
-0.13
-26.73%
SE:ELIC
Elicera Therapeutics AB
2.66
-3.37
-55.90%
SE:SPAGO
Spago Nanomedical AB
0.04
-0.10
-71.63%
SE:CANTA
Cantargia AB
1.60
-1.91
-54.36%
SE:SPRINT
Sprint Bioscience AB
3.60
2.90
415.76%
SE:FLUI
Fluicell AB
27.90
14.80
112.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.